相关实验视频
Updated: Feb 15, 2026

06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
1.6K
使用生物标志物预测性结肠炎临床缓解期患者的粘膜愈合:单中心前性试点研究
Naohiro Kato1, Ryusaku Kusunoki2, Hiroki Kamada1
1Department of Endoscopy, NHO Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Medicine
|February 13, 2026
概括
便中的calprotectin (FC),富含白蛋白的α-2糖蛋白 (LRG) 和前列腺素E主要尿代谢物 (PGE-MUM) 可以帮助确定性结肠炎 (UC) 中的粘膜愈合. 将LRG和PGE-MUM与FC结合起来,可以提高在UC缓解期间确认内镜缓解的准确性.
科学领域:
- 胃肠病学 胃肠病学
- 生物标志物发现发现
- 炎症性肠病研究研究
背景情况:
- 粘膜愈合 (MH) 对于性结肠炎 (UC) 治疗至关重要,但临床缓解并不总是保证MH.
- 便中的calprotectin (FC) 是一种经过验证的MH标志物,含有丰富的白蛋白α-2糖蛋白 (LRG) 和前列腺素E主要尿路代谢物 (PGE-MUM) 显示出类似的潜力.
- 没有直接比较LRG,PGE-MUM和FC用于预测UC中的MH.
研究的目的:
- 为了比较LRG,PGE-MUM和FC在评估内镜活动和预测UC患者粘膜愈合方面的表现.
- 评估LRG,PGE-MUM和FC单独和组合的诊断准确性,以确定内镜缓解 (ER).
主要方法:
- 一项前性观察性研究,涉及46名UC患者进行临床缓解,接受结肠镜检查.
- 测量血清LRG,尿液PGE-MUM和便FC水平. 测量血清LRG,尿液PGE-MUM和便FC水平. 测量血清LRG,尿液PGE-MUM和便FC水平.
- 评估内镜缓解 (梅奥内镜评分为0) 和组织学缓解 (盖博斯评分).
- 接收器操作特征 (ROC) 曲线分析,以确定曲线下的面积 (AUC) 和最佳切断值.
主要成果:
- 与ER患者相比,没有内镜缓解 (ER) 的患者观察到LRG,PGE-MUM和FC的中位数显著更高 (P < .05).
- 预测ER的AUC值为:FC (0.788),PGE-MUM (0.695),以及LRG (0.686). 这些值是:
- 结合LRG + FC和PGE-MUM + FC的AUC分别为0.800和0.865的改善,用于预测ER.
结论:
- LRG和PGE-MUM显示出在临床缓解UC患者中评估ER的生物标志物的潜力.
- 将LRG和PGE-MUM与FC相结合可能会提高在UC中确认ER的准确性,即使在缓解期间也是如此.
- 这些发现支持使用这些生物标志物来监测治疗疗效,并指导UC管理中的临床决策.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
541
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
541
Inflammatory Bowel Disease I: Ulcerative Colitis
1.2K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.2K
Patient-centered Care
3.1K
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.1K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.3K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.3K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
649
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
649
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.7K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.7K

